InsidersTradesSigma
Track the 东宝生物 stock price and the full insider trade history of the company, a listed issuer based in China. Shares trade on the CN market, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 东宝生物 has published 1 insider filings. Market capitalisation: €2.8bn. The latest transaction was reported on 19 December 2022 (Sale). Among the most active insiders: 孟根达日. The full history is openly available.
1
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€317
1 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,818 of 28,775 companies
39.2
score / 100
Value37
Quality41
FCF yld1.0%
Earn yld2.0%
EV/EBITDA20.1x
ROE3.2%
Gross mgn23%
Net mgn7.3%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 19 December 2022
About 东宝生物
Dongbao Bio is a company specializing in the health and pharmaceutical sector, focusing on the development and production of biological products. It is listed on the XSHE market.